View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect...

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the , to take place on Monday, May 20, 2024, at the NAS...

 PRESS RELEASE

Spero Therapeutics Announces First Quarter 2024 Operating Results and ...

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTIReceived FDA Fast Track designation for SPR206 for treatment of HABP/VABP due to CRABc and CRPACash balance of $82.3 million as of March 31, 2024; reiterate expected cash runway into late 2025 CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWI...

 PRESS RELEASE

Eyenovia Reports First Quarter 2024 Financial Results and Provides Upd...

Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0.05%, for the treatment of inflammation and pain following ocular surgery Company to host conference call and webcast today, May 15t...

 PRESS RELEASE

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th

Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th Company to host an investor conference call and webcast at 4:30pm EDT NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), an ophthalmic company with two FDA-approved products and a late-stage asset in pediatric progressive myopia, today announced that the Company will release financial results for the first quarter ended March 31, 2024 on Wednesday, May 15th, 2024, after the markets close. Following the release, Eyenovia management will host a conference call and webcast at 4:30 p.m. ET to review the financial ...

 PRESS RELEASE

Spero Therapeutics to Report First Quarter 2024 Financial Results and ...

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not inten...

 PRESS RELEASE

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Ru...

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 I...

 PRESS RELEASE

Sun Communities, Inc. Reports 2024 First Quarter Results

Sun Communities, Inc. Reports 2024 First Quarter Results       Total Revenue Increased by 3.1% Net Loss per Diluted Share of $0.22 Core FFO per Share of $1.19       Total North America Same Property NOI Increased by 7.9% North America Same Property Adjusted Blended Occupancy for MH and RVIncreased by 180 Basis Points, Year-over-Year Revenue Producing Site Gains of 233, Including 176 Transient-to-Annual RV Site Conversions       Full-Year Core FFO per Share Guidance for 2024 of $7.06 - $7.22 Guidance Range for Full-Year North America Same Property NOI Growth of 4.6% - 5.8% Southfield,...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings affirms Blackstone Mortgage Trust's Ba3 corporate fami...

Moody's Ratings (Moody's) has affirmed Blackstone Mortgage Trust, Inc.'s (BXMT) Ba3 corporate family rating (CFR) and Ba3 senior secured debt and senior secured bank credit facilities ratings. Moody's has also changed BXMT's outlook to negative from stable. RATINGS RATIONALE The outlook change t...

 PRESS RELEASE

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Produ...

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet® NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an upd...

 PRESS RELEASE

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus ...

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobetasol propionate ophthalmic suspension 0.05% for post-surgical management of pain and inflammation; both represent large multi-million-dollar opportunitiesCompany explori...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 6, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Sun Communities, Inc. Releases 2023 ESG Report

Sun Communities, Inc. Releases 2023 ESG Report Southfield, MI, April 04, 2024 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (“Sun” or the “Company”), a real estate investment trust ("REIT") that owns and operates, or has an interest in manufactured housing ("MH") and recreational vehicle ("RV") communities and marinas (collectively, the "properties"), announces the release of its 2023 Environmental, Social and Governance (“ESG”) report. “It is with a sense of pride that I reflect on our ESG achievements over the past several years, and I am pleased to share our 2023 ESG r...

 PRESS RELEASE

Eyenovia to Feature its Suite of Commercial Products and the Optejet D...

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 5-8, in Boston Will also demonstrate and discuss commercial terms for Mydcombi at the Vision Source Exchange, April 10-13, in Orlando NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the comp...

 PRESS RELEASE

Sun Communities, Inc. Announces Dates for First Quarter 2024 Earnings ...

Sun Communities, Inc. Announces Dates for First Quarter 2024 Earnings Release and Conference Call Southfield, MI, April 02, 2024 (GLOBE NEWSWIRE) -- Sun Communities, Inc. (NYSE: SUI) (the “Company”), a real estate investment trust (“REIT”) that owns and operates, or has an interest in, manufactured housing and recreational vehicle communities and marinas (collectively, the "properties"), announces it will release first quarter 2024 operating results after the market closes on Monday, April 29, 2024. The Company will host a conference call to discuss these results on Tuesday, April 30, 202...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 30, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Sun Communities Inc: 1 director

A director at Sun Communities Inc sold 2,500 shares at 128.394USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

IDEX Corporation - December 2023 (LTM): Peer Snapshot 

Compares key performance metrics against industry peers.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch